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Abstract
Introduction: In development of the American College of Rheumatology (ACR)/European League Against
Rheumatism (EULAR) rheumatoid arthritis (RA) remission definitions using clinical trials data, one criterion used to
compare different remission definitions was whether, compared with those not in remission, those in remission
had evidence of later disease stability defined by x-ray and functional status. Validation of the RA remission criteria
using observational study data is necessary before recommending their use in practice.
Methods: Using data from those who met RA criteria in the ESPOIR cohort, we matched each person in remission
with a person not in remission and then carried out analyses comparing later stability of x-ray and health
assessment questionnaire (HAQ) between the two groups. We compared the predictive validity of the same
candidate definitions of remission evaluated in the ACR/EULAR process. To minimize potential bias and produce
more stable results, we used a bootstrap resampling approach to select those not in remission, repeating the
sample matching analysis process 500 times.
Results: Results were similar to those of clinical trials analyzed for the ACR/EULAR remission criteria. Specifically, the
ACR/EULAR remission definitions using either an simple disease activity index (SDAI) ≤ 3.3, clinical disease activity
index (CDAI) ≤ 2.8 or a definition of remission requiring tender joint count, swollen joint count, patient global
assessment all ≤ 1 performed as well or better than other candidate definitions of remission in terms of predicting
later x-ray and function stability.
Conclusions: ACR/EULAR definitions of remission developed for trials are similarly valid in observational studies in
RA and could be used in practice.
Introduction
Recently a committee consisting of members of the Amer-
ican College of Rheumatology (ACR) and the European
League Against Rheumatism (EULAR) with help from
Outcome Measures in Rheumatoid Arthritis Clinical
Trials (OMERACT) produced a new rheumatoid arthritis
(RA) remission definition for use in clinical trials [1].
While the committee developed a remission definition
using only trial data, suggestions were made for remission
definitions to be used in practice. The performance of the
trial-based definitions in practice-based settings and of
those proposed for use in practice has not been fully
examined. If these new RA remission definitions perform
as comparably in observational studies as in randomized
clinical trials, then these might also be used as practice-
based criteria.
While studies have examined the performance of these
criteria in practice-based observational studies [2], one of
the central elements of validating the criteria was to test
their predictive validity, that is, whether being in remission
at one time predicted good outcomes later. To our knowl-
edge, there has been no attempt to corroborate the ACR/
EULAR committee’s examination of the predictive validity
of different remission definitions in practice-based studies.
Evidence from such studies could validate the use of the
committee’s recommendations in practice.
In this paper, we apply a matched bootstrap re-sampling
method to an observational study, the French ESPOIR
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study, to validate the performance of the provisional ACR/
EULAR RA remission criteria for use in practice.
Materials and methods
The ESPOIR cohort
The ESPOIR cohort [3,4] is a prospective observational
study of adults aged 18 to 70 years recruited from 14
regions across France under the auspices of the French
Society of Rheumatology, and with a protocol approved
by the Montpelier University ethical committee. To be
included, patients had to present with inflammatory
arthritis lasting for 6 weeks to 6 months, involving more
than two joints and diagnosed by the referring physician
as RA or RA-like (that is, a high suspicion of RA).
Patients had never previously undergone treatment with
a disease-modifying anti-rheumatic drug (DMARD) or
steroids. Patients were excluded if the referring physi-
cian judged they had other clearly defined rheumatic
diseases.
Patients were recruited from general practitioners
(GPs) and rheumatologists. Data were collected by the
regional university rheumatology department which did
not interfere with patient treatment. Patients were routi-
nely treated and followed up by private rheumatologists
in the geographical area, and in exceptional cases, by
GPs with a special interest in rheumatology. All patients
were followed by the same investigator every 6 months
during the first two years and every year thereafter. Data
on medical history, socio-economic and demographic
characteristics, clinical, biological, radiographic and
genetic parameters were also collected. Baseline and
one-year radiographs of hands, wrists and feet were read
according to the van der Heijde Sharp score, blinded to
patient identity, patient characteristics and treatment,
but with known time order for reasons of sensitivity to
change [5]. The main radiographic results were recently
published [4]. The first patients were enrolled in
December 2002, and in total 813 patients were included,
of whom 641 met the 2010 ACR/EULAR classification
criteria for RA. This latter group is the focus of this
report.
Definition of remission
In the ACR/EULAR RA definition of remission for clinical
trials, remission was defined based on whether a patient
was in remission 6 months after they were randomized to
an RA treatment, and good outcomes (after remission)
were examined 12 to 24 months after randomization.
For this analysis, we defined the remission group as
those who ever reached the ACR/EULAR RA remission
criteria during the study, and defined the time to remis-
sion as the time they first reached remission. For those
who were already in remission when they entered the
study, time to remission was set to zero.
Those who never reached remission during the study
were defined as the non-remission group.
To avoid the problem of making an arbitrary choice of a
fixed time window to non-remission, we used a matched
bootstrap re-sampling method to determine the time to
non-remission from the non-remission group, so that
potential bias and random variation were averaged out.
Without re-sampling, we would choose one random time
point for each person not in remission to match to a per-
son in remission. With bootstrap re-sampling, we could
create a more robust, precise and valid sampling of the
range of values for persons not in remission. By the Law
of Large Numbers, the sample mean approaches the popu-
lation mean when sample size gets large, whereas a single
observation is not a precise or especially valid estimator of
the population mean.
We used Effron’s Boostrap method [6,7] which allows
one to estimate sample distributions of parameter esti-
mates, and quantify uncertainty by calculating standard
errors and confidence intervals of the parameter estimates
so that statistical inference can be made. The basic idea of
the bootstrap method is as follows: Step 1: resample; cre-
ate a bootstrap sample with the same size as the original
sample by resampling randomly with replacement from
the original data. Step 2: perform the necessary data analy-
sis using the bootstrap sample as if it were the original
sample, and obtain parameter estimates of interest. Step 3:
repeat Step 1 and Step 2 many times (depending on the
nature of parameter estimation) and obtain the distribu-
tion of the parameter estimate. Step 4: construct standard
errors and confidence intervals for parameters of interest.
Application to the ESPOIR study for validation of ACR/
EULAR RA remission criteria
We applied the bootstrap sampling approach to our eva-
luation of the predictive validity of different ways of defin-
ing remission in RA. We carried out analyses for all
patients in the ESPOIR study starting at the baseline exam-
ination, and also in the subset of patients meeting ACR/
EULAR criteria for RA at the baseline ESPOIR examina-
tion. We defined the remission group as persons who ever
reached RA remission during the study and defined time
to remission as the first time after entry that they reached
remission according to successive 6-month windows, and
then the proportions with remission within each 6-month
window were calculated. Then bootstrap samples were
selected for the non-remission group according to the
same proportion from the remission group (for example, if
25% of the patients reaching remission reached it during
the first 6-month window, we would choose 25% of the
non-remission group in this window also.)
Definition of outcome
As with the ACR/EULAR committee’s approach to
defining remission [1], we examined predictive validity,
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defining it based on good radiographic and functional
(health assessment questionnaire, HAQ) outcomes. For
the ESPOIR cohort, we examined good outcomes over
the interval of 12 to 24 months after the patient first
reached remission.
We defined a good outcome for radiographic damage
and physical function separately, and then characterized
patients who had good outcomes on both measures.
The good radiographic outcome was defined as stable
x-ray diagnosis over one year (12 to 24 months after
achieving remission) (change in total SHARP or van der
Heijde modified total SHARP scores ≤ 0). A good func-
tional outcome was defined as stable HAQ assessment
[8] and maintenance of a low HAQ (HAQ change ≤ 0
and HAQ ≤ 0.5 during the year 12 to 24 months after
achieving remission).
Positive likelihood ratios and their confidence intervals
were computed using. a standard positive ratio calculator
[9]. Likelihood ratios were used to compare the proportion
of patients with RA in remission who had a good outcome,
to the proportion of patients with RA not in remission
who had a good outcome. To rank candidate definitions of
remission, we used the P-value from the logistic regression
chi-square test.
Results
Table 1 shows the characteristics of patients in the
ESPOIR study at the baseline examination. Patients
tended to be female and to have active disease as evi-
denced by the presence of multiple tender and swollen
joints.
We examined the members of the ESPOIR cohort who
met the criteria for RA [10] to evaluate the predictive
validity of different definitions of remission as tested by
the ACR/EULAR committee. Table 2 shows that the two
new RA remission definitions (28 tender joint count
(TJC28), 28 swollen joint count (SJC28), C-reactive protein
(CRP) and patient global assessment (PtGA) ≤ 1, and sim-
ple disease activity index (SDAI) ≤ 3.3) performed among
the best of the candidate remission definitions in predict-
ing good outcomes for radiographic and HAQ stability
during the one-year follow-up (in both the positive likeli-
hood ratio and P-value).
We also confirmed that the ACR/EULAR committee
recommendations for defining remission in clinical prac-
tice (TJC28, SJC28 and PtGA ≤ 1, and CDAI ≤ 2.8)
worked well, in that those who reached remission had a
higher chance of good future outcomes than those not
reaching remission.
Discussion
An evaluation of the predictive validity of different candi-
date definitions of remission in the ESPOIR cohort, a prac-
tice-based observational study, shows that the new ACR/
EULAR trial-based remission definitions have high predic-
tive validity for good outcomes in clinical practice.
Practice-based definitions suggested by the committee
focused on those definitions that did not include acute
phase reactants, which were felt to be difficult to obtain
during a clinic visit. Our analyses validated the commit-
tee’s choices and suggested that those recommended
would perform well in practice. While the definitions
recommended by the committee did not necessarily have
the highest positive predictive values and lowest P-values
of all those tested, they performed well, and using these
definitions, the proportion in remission doing well was
subsequently within 2% of the top-performing definitions
(see Table 2).
Predictive validity was a critical element in the selection
of definitions of remission for RA. It was felt by the ACR/
EULAR committee that persons in remission at one time
point should have more favorable later RA outcomes than
persons not in remission. Our data suggest that the RA
patients who attain the recommended definitions of remis-
sion in practice have a high likelihood of good future out-
comes. As in the trial data analysis, our results suggest
that the Boolean and SDAI/CDAI definitions of remission
are better at predicting good outcomes than disease activ-
ity score (DAS)-based definitions of remission.
One other study has examined the relationship
between different definitions of RA remission and func-
tional and radiographic status [11]. While also focused
on patients with recent onset disease, this used data from
a trial, the BeSt study, which was not conducted in a
practice based setting. In this study, versions of the DAS
Table 1 ESPOIR study demographics and disease
characteristics for patients meeting ACR/EULAR
classification criteria for rheumatoid arthritis at entry.
Variables
Number 641
Age, years 48.5 (12.2)
Sex, number (%) female 499 (77.8)
Tender joint count, score from 0 to 28 9.8 (7.2)
Swollen joint count, score from 0 to 28 8.2 (5.5)
CRP, mg/dL 2.1(3.3)
Patient global assessment, cm from 0 to 10 6.2 (2.5)
Physician Global Assessment in cm from 0 to10 5.4 (2.2)
Pain score in cm from 0 to 10 5.7 (2.6)
HAQ, score from 0 to 3 1 (0.7)
Modified total Sharp score 6.4 (10.5)
IgM rheumatoid factor positivity, n (%) 367 (57.2)
Anti-CCP positivity, n (%) 313 (48.8)
Results presented as mean (SD) unless stated otherwise. Anti-CCP: test
positive for antibody to cyclic citullinated protein
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were as strongly associated with good outcomes as the
ACR/EULAR-recommended definitions. It should be
noted that the design of the BeSt study, in which patient
treatment was guided by the DAS score [12] dictates that
outcomes cannot be independent of the DAS score, and
this makes it likely that DAS scores would be associated
with major outcomes. Thus, it is not surprising that in
this analysis of BeSt being in DAS remission portended
good future outcomes.
Evaluating predictors of outcomes in observational stu-
dies like ESPOIR is not as straightforward as doing these
analyses in clinical trials. First, it is hard to define a fixed
time of remission. Among patients in some cohorts
(although not in ESPOIR) we do not know when RA
treatment was initiated; the majority might have already
received multiple RA treatments before they enter the
study. Second, some patients might already be in remis-
sion when they enter the study. Since the treatment pro-
tocol is not controlled as in a trial, it does not make
sense to set a fixed time point after cohort entry as the
time of remission, because some patients will reach
remission at other time points. Also, because patient
population heterogeneity is higher in observational stu-
dies than in clinical trials, some patients may respond
more slowly or more quickly to new treatments than
those in a trial.
There are also challenges in choosing a time point for
“non-remission” so that valid comparisons can be made
between non-remission and remission groups. The time
to a non-event, that is, time to non-remission for a
patient in an observational study, is either impossible to
define or can only be arbitrarily defined. For those never
reaching remission, it can be any time from baseline to
the end of the study. Arbitrary fixing of the time of non-
remission may introduce bias. Besides, since the time of
remission for patients achieving remission is dynamic, it
makes sense not to fix the non-remission time. We used
bootstrap methods to create samples of non-remission
patients. The well established advantages of bootstrap
methods are that 1) they require fewer assumptions (for
example, normality of the parameter estimates is not
required); 2) they produce more precise and stable (that
is, valid) parameter estimates than classical methods;
3) standard errors, confidence intervals and other para-
meters are easy to derive based on the distribution of the
bootstrap parameter estimates to make inferences; and
4) the results are stable [6,7].
There are a number of limitations to our study. First, we
limited our comparison of candidate definitions of remis-
sion to those evaluating predictive validity. Other consid-
erations are important too, such as face and content
validity, feasibility, and reproducibility. The ACR/EULAR
Table 2 Comparison of the ACR/EULAR RA remission definition candidate for patients meeting ACR/EULAR
classification criteria for rheumatoid arthritis (ESPOIR STUDY).
Prevalence of good outcome in patients**:
Candidate remission definition (* definitions are
those recommended by ACR/EULAR)




TJC28, SJC28, CRP ≤ 1 25% (29/118) 12% 1.4 (1.1, 1.7) 0.0526
TJC28, SJC28, CRP, PhGA ≤ 1 32% (23/71) 13% 1.9 (1.4, 2.7) 0.0034
TJC28, SJC28, CRP, PtGA ≤ 1* 39% (23/59) 12% 2.4 (1.6,3.5) 0.0002
TJC28, SJC28, CRP, pain ≤ 1 34% (24/70) 13% 2.0 (1.4, 2.8) 0.0023
TJC28, SJC28, CRP, PhGA, PtGA ≤ 1 40% (22/55) 12% 2.6 (1.7, 3.8) 0.0002
TJC28, SJC28, CRP, PhGA, pain ≤ 1 38% (21/55) 13% 2.3 (1.6, 3.5) 0.0006
TJC28, SJC28, CRP, PtGA, pain ≤ 1 40% (21/53) 12% 2.6 (1.7, 3.9) 0.0002
TJC28, SJC28, CRP, PhGA, PtGA, pain ≤ 1 39% (20/51) 13% 2.5 (1.6, 3.9) 0.0005
Index-based definition
DAS28 < 2.6 25% (35/146) 11% 1.3 (1.1, 1.5) 0.0383
DAS28 < 2.0 28% (24/85) 12% 1.6 (1.2, 2.2) 0.0148
SDAI ≤ 3.3* 39% (27/69) 12% 2.3 (1.6, 3.2) 0.0001
Definitions without CRP (for clinical practice)
TJC28, SJC28, PhGA, PtGA ≤ 1 38% (23/60) 13% 2.3(1.6,3.4) 0.0003
TJC28, SJC28, PtGA < 1* 37% (24/65) 12% 2.0(1.4,2.9) 0.0004
CDAI ≤ 2.8* 36% (26/72) 12% 2.0(1.5,2.8) 0.0005
*Average values calculated from the 500 bootstrap samples of patients not in remission.
**Good outcome defined in a person when they had both good function and good radiographic outcomes (see Methods). CDAI: clinical disease activity index;
CRP: C-reactive protein; DAS: disease activity score; EULAR: European League Against Rheumatism; PtGA: patient global assessment; PhGA: physician global
assessment; RA: rheumatoid arthritis; SJC28: 28 swollen joint count; TJC28: 28 tender joint count.
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committee considered some but not all of these in its
deliberations. Remission was defined by the ACR/EULAR
committee using a data-driven consensus process. This
type of process used for all consensus efforts in rheuma-
tology combines expert opinion and data analysis. Prior to
data analysis, there was input from the committee (that
included experts in RA research), as to which measures
should be included in a remission definition; the commit-
tee dictated that swollen and tender joint counts and CRP
were mandatory. Although we added other variables to
these, this committee decision determined subsequent
variable selection and heavily influenced the selection of
candidate remission definitions. This could be regarded a
controversial; other recommendations or even an agnostic
variable-driven approach might have produced a different
definition of remission and our analyses in this paper
might also have tested other options as definitions, ones
not considered by the ACR/EULAR committee.
Among the limitations of the study is that we studied
only one observational cohort. More observational studies
from different geographical regions and study populations
are needed to make sure that our single validation is gen-
eralizable to other samples of patients. However, the data
from in this study are from a comprehensive large nation-
wide cohort of persons with RA.
Conclusions
The ACR/EULAR definitions of remission were developed
using data from trials. We examined the predictive validity
of these definitions of remission in the ESPOIR cohort, a
practice-based observational cohort from France. We
found that persons in ACR/EULAR remission in ESPOIR
had a high rate of later radiographic and functional stabi-
lity, and suggest that these definitions of remission are
valid in clinical practice settings.
Abbreviations
ACR: American College of Rheumatology; CDAI: clinical disease activity index;
CRP: C-reactive protein; DAS: disease activity score; DMARD: disease
modifying anti-rheumatic drugs; EULAR: European League Against
Rheumatism; HAQ: health assessment questionnaire; OMERACT: Outcome
Measures in Rheumatoid Arthritis Clinical Trials; PtGA: patient global
assessment; RA: rheumatoid arthritis; SDAI: simple disease activity index;
SJC28: 28 swollen joint count; TJC28: 28 tender joint count.
Acknowledgements
We also wish to thank Cedric Lukas who did expert radiographic reading
and all the investigators who recruited and followed the patients (F
Berenbaum, Paris-Saint Antoine; MC Boissier, Paris-Bobigny; A Cantagrel,
Toulouse; B Combe, Montpellier; M Dougados, Paris-Cochin; P Fardelonne
and P Boumier, Amiens; B Fautrel and P Bourgeois, Paris-La Pitié; RM Flipo,
Lille; P Goupille, Tours; F Liote, Paris-Lariboisière; × Le Loet and O Vittecoq,
Rouen; × Mariette, Paris Bicetre; O Meyer, Paris Bichat; A.Saraux, Brest; T
Schaeverbeke, Bordeaux; J Sibilia, Strasbourg).
Dr Zhang was supported by an ACR REF 2010 American College of
Rheumatology New Investigator Award. This work was supported by NIH
AR47785. For the ESPOIR cohort, an unrestricted grant from Merck Sharp
and Dohme (MSD) was allocated for the first 5 years of the ESPOIR cohort.
Two additional grants from INSERM were obtained to support part of the
biological database. The French Society of Rheumatology, Abbott, Wyeth-
Pfizer and Roche-Chugaï also supported the ESPOIR cohort study.
Author details
1Clinical Epidemiology Research and Training Unit, Boston University School
of Medicine, Boston, MA 02118, USA. 2Department of Rheumatology,
Lapeyronie Hospital, Montpellier I University, UMR 5535 Montpellier, France.
3Arthritis Research UK Epidemiology Unit, University of Manchester,
Manchester, M13 9PT, UK.
Authors’ contributions
BZ oversaw the analysis, conceptualized the project and drafted the
manuscript. BC provided the data and revised the manuscript. NR carried
out the analysis of the ESPOIR cohort and revised the manuscript. DTF
conceptualized the project, directed the team and revised the manuscript.
All authors have read and approved the final manuscript.
Competing interests
The authors declare that they have no competing interests.
Received: 5 March 2012 Revised: 16 May 2012 Accepted: 29 June 2012
Published: 29 June 2012
References
1. Felson DT, Smolen JS, Wells G, Zhang B, van Tuyl LH, Funovits J, Aletaha D,
Allaart CF, Bathon J, Bombardieri S, Brooks P, Brown A, Matucci-Cerinic M,
Choi H, Combe B, de Wit M, Dougados M, Emery P, Furst D, Gomez-
Reino J, Hawker G, Keystone E, Khanna D, Kirwan J, Kvien TK, Landewé R,
Listing J, Michaud K, Martin-Mola E, Montie P, et al: American College of
Rheumatology/European League Against Rheumatism provisional
definition of remission in rheumatoid arthritis for clinical trials. Arthritis
Rheum 2011, 63:573-586.
2. Shahouri SH, Michaud K, Mikuls TR, Caplan L, Shaver TS, Anderson JD,
Weidensaul DN, Busch RE, Wang S, Wolfe F: Remission of rheumatoid
arthritis in clinical practice: Application of the American College of
Rheumatology/European League Against Rheumatism 2011 remission
criteria. Arthritis Rheum 2011, 63:3204-3215.
3. Combe B, Benessiano J, Berenbaum F, Cantagrel A, Daures JP, Dougados M,
Fardellone P, Fautrel B, Flipo RM, Goupille P, Guillemin F, Le Loet X,
Logeart I, Mariette X, Meyer O, Ravaud P, Rincheval N, Saraux A,
Schaeverbeke T, Sibilia J: The ESPOIR cohort: a ten-year follow-up of early
arthritis in France: methodology and baseline characteristics of the 813
included patients. Joint bone spine 2007, 74:440-445.
4. Lukas C, Combe B, Ravaud P, Sibilia J, Landew R, van der Heijde DM:
Favorable effect of very early disease-modifying antirheumatic drug
treatment on radiographic progression in early inflammatory arthritis:
Data from the Etude et Suivi des polyarthrites indifferenciees recentes
(study and followup of early undifferentiated polyarthritis). Arthritis
Rheum 2011, 63:1804-1811.
5. Van der Heijde DM: How to read radiographs according to the Sharp/van
der Heijde method. J Rheumatol 2000, 27:261-263.
6. Efron B: Bootstrap methods: another look at the jackknife. The Annals of
Statistics 1979, 7:1-26.
7. Efron B, Tibshirani R: An Introduction to the Bootstrap Boca Raton, FL:
Chapman & Hall/CRC; 1993.
8. Fries JF, Spitz P, Kraines RG, Holman HR: Measurement of patient outcome
in arthritis. Arthritis Rheum 1980, 23:137-145.
9. VassarStats: Website for Statistical Computation VassarStats 2012 [http://
vassarstats.net/].
10. Aletaha D, Neogi T, Silman AJ, Funovits J, Felson DT, Bingham CO III,
Birnbaum NS, Burmester GR, Bykerk VP, Cohen MD, Combe B,
Costenbader KH, Dougados M, Emery P, Ferraccioli G, Hazes JM, Hobbs K,
Huizinga TW, Kavanaugh A, Kay J, Kvien TK, Laing T, Mease P, Ménard HA,
Moreland LW, Naden RL, Pincus T, Smolen JS, Stanislawska-Biernat E,
Symmons D, et al: 2010 rheumatoid arthritis classification criteria: an
American College of Rheumatology/European League Against
Rheumatism collaborative initiative. Ann Rheum Dis 2010, 69:1580-1588.
11. Klarenbeek NB, Koevoets R, Van der Heijde DM, Gerards AH, Ten WS,
Kerstens PJ, Huizinga TW, Dijkmans BA, Allaart CF: Association with joint
damage and physical functioning of nine composite indices and the
Zhang et al. Arthritis Research & Therapy 2012, 14:R156
http://arthritis-research.com/content/14/3/R156
Page 5 of 6
2011 ACR/EULAR remission criteria in rheumatoid arthritis. Ann Rheum
Dis 2011, 70:1815-1821.
12. Goekoop-Ruiterman YP, de Vries-Bouwstra JK, Allaart CF, van Zeben D,
Kerstens PJ, Hazes JM, Zwinderman AH, Ronday HK, Han KH, Westedt ML,
Gerards AH, van Groenendael JH, Lems WF, van Krugten MV, Breedveld FC,
Dijkmans BA: Clinical and radiographic outcomes of four different
treatment strategies in patients with early rheumatoid arthritis (the BeSt
study): a randomized, controlled trial. Arthritis Rheum 2005, 52:3381-3390.
doi:10.1186/ar3896
Cite this article as: Zhang et al.: Validation of ACR/EULAR definition of
remission in rheumatoid arthritis from RA practice: the ESPOIR cohort.
Arthritis Research & Therapy 2012 14:R156.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color figure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Zhang et al. Arthritis Research & Therapy 2012, 14:R156
http://arthritis-research.com/content/14/3/R156
Page 6 of 6
